QCG
ADCT icon

Quadrant Capital Group’s ADC Therapeutics ADCT Stock Holding History

Quadrant Capital Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$649 Hold
173
– – ﹤0.01% 2619
2025
Q4 		$611 Hold
173
– – ﹤0.01% 2636
2025
Q3 		$692 Buy
+173
New +$545 ﹤0.01% 2584

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Quadrant Capital Group's ADCT Position: Q1 2026 in Review

Quadrant Capital Group held its ADC Therapeutics (ADCT) position steady in Q1 2026 at 173 shares worth $649. The position accounts for ﹤0.01% of the portfolio, ranked #2619.

Quadrant Capital Group first reported a position in ADCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $692 in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Quadrant Capital Group held 173 shares of ADC Therapeutics worth $649 as of Q1 2026.
  • Quadrant Capital Group left its ADC Therapeutics share count unchanged in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2619 holding.
  • Quadrant Capital Group first reported a position in ADC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Quadrant Capital Group's ADC Therapeutics position peaked at $692 in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.